The US Court of Appeals for the Federal Circuit affirmed a
Patent Trial and Appeal Board (PTAB) finding that tribal immunity
does not apply to inter partes review (IPR) proceedings.
Saint Regis Mohawk Tribe v. Mylan Pharmaceuticals, Inc., et
al., Case Nos. 18-1638, -1639, -1640, -1641, -1642, -1643
(Fed. Cir. July 20, 2018) (Moore, J).
The appeal stems from a multi-front dispute between Allergan and
various generic drug manufacturers regarding patents related to
Allergan's Restasis product, a treatment for alleviating the
symptoms of chronic dry eye. In 2015, Allergan sued the generic
drug manufactures in the Eastern District of Texas, alleging
infringement of its Restasis patents based on their filings of
abbreviated new drug applications. In 2016, Mylan petitioned for
IPR of Restasis patents, and the other generic drug manufacturers
subsequently filed similar petitions. The PTAB instituted IPR and
scheduled a consolidated oral hearing for September 2017.